NOT KNOWN FACTS ABOUT COPYRIGHT 1 MG-SEMAGLUTIDE

The demo reached both its Key endpoints, with semaglutide two.4 mg demonstrating statistically considerable and top-quality improvements in liver fibrosis without worsening of steatohepatitis, in addition to resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH when compared to placebo.oneDistinct Populations Based on